Source comparison
DAC Versus Non-DAC: How Formulation Changes Dosing
The presence or absence of drug affinity complex (DAC) modification is the single most important variable determining how CJC-1295 is administered in research. CJC-1295 with DAC has a plasma half-life of 6–8 days, allowing once-weekly administration while main
This comparison does not assign a generated winner or score.
- The presence or absence of drug affinity complex (DAC) modification is the single most important variable determining how CJC-1295 is administered in research. CJC-1295 with DAC has a plasma half-life of 6–8 days, allowing once-weekly administration while maintaining stable IGF-1 elevation. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) has a half-life of approximately 30 minutes, requiring 2–3 injections per week to sustain therapeutic plasma levels.
- DAC modification works by binding the peptide to serum albumin, creating a reservoir that releases active peptide gradually over days rather than hours. This eliminates the sharp GH spike-and-crash pattern seen with non-DAC formulations and produces a more physiological elevation that better mimics endogenous GHRH pulsatility. Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 with DAC increased mean IGF-1 levels by 60% above baseline for up to two weeks following a single 60mcg/kg dose.
- Non-DAC protocols typically dose CJC-1295 at 100–200mcg per injection, administered 2–3 times weekly in the evening to align with nocturnal GH secretion peaks. DAC protocols use 1–2mg per injection once weekly, often on a fixed day (e.g., Monday morning) to simplify compliance tracking in multi-week studies. The formulation distinction is not interchangeable. Substituting DAC for non-DAC without adjusting dose and frequency invalidates pharmacokinetic assumptions entirely.